Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This trial is studying the side effects and best dose of ixabepilone when given together with
pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women
with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer or
metastatic breast cancer. Drugs used in chemotherapy, such as ixabepilone and pegylated
liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Doxorubicin Epothilone B Epothilones Liposomal doxorubicin